ProQR Therapeutics NV
PRQR2.190USD
+0.130+6.31%
收盘 09/18, 16:00（美东）报价延迟15分钟
235.89M总市值
亏损市盈率 TTM
关于 ProQR Therapeutics NV 公司
ProQR Therapeutics NV 是一家位于荷兰的临床前生物制药公司。该公司致力于发现和开发用于治疗严重遗传疾病的核糖核酸 (RNA) 疗法。该公司设计的治疗候选药物专门针对和修复从突变基因转录而来的缺陷信使 RNA 或信使核糖核酸 (mRNA)，以恢复正常或野生型蛋白质的表达和功能。其候选产品包括 QR-010（一种用于治疗囊性纤维化 (CF) 的 RNA 寡核苷酸）和 QR-110（一种用于治疗莱伯氏先天性黑蒙 (LCA) 的寡核苷酸）。
公司简介
公司代码PRQR
公司名称ProQR Therapeutics NV
上市日期Sep 18, 2014
CEOMr. Daniel Anton de Boer
员工数量166
证券类型Ordinary Share
年结日Sep 18
公司地址Zernikedreef 9
城市LEIDEN
上市交易所NASDAQ Capital Market Consolidated
国家Netherlands
邮编2333 CK
电话31881667000
网址https://www.proqr.com/
公司代码PRQR
上市日期Sep 18, 2014
CEOMr. Daniel Anton de Boer
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Begona Carreno, Ph.D.
Ms. Begona Carreno, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Eli Lilly and Company
16.04%
Van Herk Investments
12.60%
Adage Capital Management, L.P.
6.27%
Privium Fund Management BV
4.74%
Affinity Asset Advisors LLC
3.32%
其他
57.03%
持股股东
持股股东
占比
Eli Lilly and Company
16.04%
Van Herk Investments
12.60%
Adage Capital Management, L.P.
6.27%
Privium Fund Management BV
4.74%
Affinity Asset Advisors LLC
3.32%
其他
57.03%
股东类型
持股股东
占比
Hedge Fund
20.24%
Corporation
16.04%
Family Office
12.60%
Investment Advisor
10.72%
Investment Advisor/Hedge Fund
4.75%
Research Firm
3.30%
Individual Investor
2.00%
Bank and Trust
0.06%
其他
30.29%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
122
61.04M
57.95%
-6.05M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
2023Q2
170
45.68M
56.49%
-13.40M
2023Q1
180
47.05M
58.19%
-9.38M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Eli Lilly and Company
16.90M
16.06%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
11.50M
10.93%
+40.00K
+0.35%
May 23, 2025
Adage Capital Management, L.P.
8.10M
7.7%
-1.50M
-15.62%
Mar 31, 2025
Privium Fund Management BV
4.99M
4.74%
--
--
Mar 31, 2025
Affinity Asset Advisors LLC
3.28M
3.12%
+459.51K
+16.27%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.36M
1.3%
+899.68K
+193.96%
Mar 31, 2025
Sio Capital Management, LLC
2.05M
1.95%
--
--
Mar 31, 2025
abrdn Inc.
1.85M
1.76%
+1.85M
--
Mar 31, 2025
Kynam Capital Management LP
1.75M
1.66%
--
--
Mar 31, 2025
Dafna Capital Management, LLC
1.57M
1.49%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
0%
Avantis International Small Cap Value ETF
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
Avantis International Small Cap Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
